Successful trials for AstraZeneca’s blood cancer drug continue

AstraZeneca Plc announced its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month.

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.

Calquence, which is already approved by the U.S. drug regulator to treat a rare type of blood cancer, also met the primary endpoint in a trial in May testing the drug in comparison with available treatment.

 

Via Reuters

Discover more from The Dispatch

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights